论文部分内容阅读
目的探讨碘131I肝癌单抗片段HAb18F(ab)2灌注治疗原发性肝癌的疗效及不良反应。方法36例原发性肝癌病例均采用Seldinger技术股动脉穿刺插管至肝固有动脉,并经导管注入131I肝癌单抗片段HAb18F(ab)2,每公斤体重0.75 mCi。结果36例原发性肝癌患者治疗后6、121、8和24个月生存率分别为83.3%、58.3%、53.0%和44.4%。中位生存时间为19个月。未发生与治疗药物相关的严重并发症。结论131I肝癌单抗片段HAb18F(ab)2经导管肝固有动脉内注射对原发性肝癌的治疗是安全、有效的。
Objective To investigate the curative effect and adverse reactions of HAb18F (ab) 2 perfusion of Iodine 131I hepatoma with monoclonal antibody to primary hepatocellular carcinoma. Methods Thirty-six patients with primary liver cancer were treated with Seldinger technique. The femoral artery was punctured into the proper hepatic artery. The 131I hepatoma McAb HAb18F (ab) 2 was transplanted into the peritoneal cavity at 0.75 mCi per kilogram of body weight. Results The survival rates of 36 patients with primary liver cancer at 6, 121, 8 and 24 months after treatment were 83.3%, 58.3%, 53.0% and 44.4%, respectively. The median survival time was 19 months. There were no serious complications associated with the medication. Conclusion The treatment of primary liver cancer with 131I hepatoma McAb HAb18F (ab) 2 transcatheter intrahepatic arterial injection is safe and effective.